Corient Private Wealth LP Purchases New Holdings in United Therapeutics Corporation $UTHR

Key Points

• Corient Private Wealth purchased 15,582 shares of United Therapeutics worth approximately $8.4 million in the second quarter. Institutional ownership stands at 94.08%, with BlackRock, Wellington Management and Avoro Capital also holding significant positions.
• United Therapeutics reported quarterly EPS of $7.27, beating analyst expectations of $6.86, although revenue of $783.3 million declined 1.9% year over year and fell short of estimates.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $646, while company insiders sold 404,575 shares valued at approximately $216.7 million over the past 90 days.

Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,582 shares of the biotechnology company's stock, valued at approximately $8,443,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in United Therapeutics in the second quarter valued at $2,868,735,000. Wellington Management Group LLP boosted its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Jupiter Topco LLC bought a new stake in United Therapeutics in the 2nd quarter valued at $450,140,000. Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC grew its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $515.46 on Monday. The stock has a 50-day moving average price of $530.46 and a two-hundred day moving average price of $539.16. United Therapeutics Corporation has a 12 month low of $303.08 and a 12 month high of $609.35. The company has a market capitalization of $22.11 billion, a PE ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the company posted $6.41 EPS. The business's revenue was down 1.9% on a year-over-year basis. As a group, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $22,185,323.93. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 404,575 shares of company stock valued at $216,652,640. Company insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on UTHR shares. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source